Multiple Assemblies exist for SMTL entry 6ut0
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer; X-RAY DIFFRACTION 1.94 Å

	SMTL ID 6ut0.1 Ligands GUANOSINE-5'-DIPHOSPHATE; MAGNESIUM ION; {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-[(2S)-2-fluoropropanoyl]piperazin-2-yl}acetonitrile Polypeptides GTPase KRas Oligo-state monomer
	SMTL ID 6ut0.2 Ligands GUANOSINE-5'-DIPHOSPHATE; MAGNESIUM ION; {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-[(2S)-2-fluoropropanoyl]piperazin-2-yl}acetonitrile Polypeptides GTPase KRas Oligo-state monomer
	SMTL ID 6ut0.3 Ligands GUANOSINE-5'-DIPHOSPHATE; MAGNESIUM ION; {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-[(2S)-2-fluoropropanoyl]piperazin-2-yl}acetonitrile Polypeptides GTPase KRas Oligo-state monomer
	SMTL ID 6ut0.4 Ligands GUANOSINE-5'-DIPHOSPHATE; MAGNESIUM ION; {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-[(2S)-2-fluoropropanoyl]piperazin-2-yl}acetonitrile Polypeptides GTPase KRas Oligo-state monomer